SCHEMBL761237

SCHEMBL761237

CN1C(=O)CCc2cc(C(C)(C)C)ccc21

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 9/20 0.50
CYP11B1 P15538 7/20 0.50
CYP1A2 P05177 2/20 0.50
CYP17A1 P05093 1/20 0.50
CYP19A1 P11511 1/20 0.50
TMEM97 Q5BJF2 1/20 0.46
BRD4 O60885 1/20 0.45
CREBBP Q92793 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE3A Q14432 1/20 0.45
TP53 P04637 1/20 0.44
TRIM24 O15164 3/20 0.44
NR1H3 Q13133 2/20 0.44
NR1H2 P55055 1/20 0.44
ATAD2 Q6PL18 1/20 0.40
SYK P43405 1/20 0.39
TYRO3 Q06418 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23051012 0.92 TP53 (0.50) CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1
SCHEMBL10133811 0.87 NR1H3 (0.42) CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1
SCHEMBL762355 0.86 TRIM24 (0.44) CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1
SCHEMBL12245376 0.86 TRIM24 (0.47) TRIM24NR1H3
SCHEMBL19910561 0.79 TP53 (0.42) TMEM97TP53NR1H3NR1H2ATAD2
SCHEMBL422074 0.79 SRD5A1 (0.58) CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1
SCHEMBL13386729 0.79 ATAD2 (0.47) CYP11B2CYP11B1CYP1A2TP53ATAD2
SCHEMBL3591114 0.77 CYP11B2 (0.51) CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1
SCHEMBL265640 0.77 SRD5A1 (0.59) CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1
SCHEMBL736131 0.77 ATAD2 (0.64) CYP11B2CYP11B1CYP1A2CYP17A1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2020-07-30 US disclosed
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES ALEXION PHARMACEUTICALS, INC. 2018-07-05 US disclosed
US-9868729-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2018-01-16 US disclosed
US-9868729-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2018-01-16 US disclosed
US-9579320-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2017-02-28 US disclosed
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-10-22 US disclosed
US-20150094298-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2015-04-02 US disclosed
US-8937070-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2015-01-20 US disclosed
US-20140031361-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. 2014-01-30 US disclosed
US-8501944-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-8349860-B2 Inhibitors of syk and JAK protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-01-08 US disclosed
US-20120129867-A1 INHIBITORS OF PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-04-26 US disclosed
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed
US-7705004-B2 Protein kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-04-27 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed
US-20090054425-A1 PROTEIN KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 CYP11B2 1337/4885CYP11B1 1249/4885CYP1A2 1714/4885
US-20150297595-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 CYP11B2 1071/4885CYP11B1 854/4885CYP1A2 1102/4885
US-20120129867-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 CYP11B2 1337/4885CYP11B1 1249/4885CYP1A2 1714/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP CYP11B2 1579/4885CYP11B1 1168/4885CYP1A2 540/4885
US-20120101275-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 CYP11B2 1071/4885CYP11B1 854/4885CYP1A2 1102/4885
US-20200239458-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 CYP11B2 1337/4885CYP11B1 1249/4885CYP1A2 1714/4885
US-20180186783-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 CYP11B2 1337/4885CYP11B1 1249/4885CYP1A2 1714/4885
US-20090054425-A1 PROTEIN KINASE INHIBITORS SYK, JAK2, BTK CYP11B2 4518/4885CYP11B1 4149/4885CYP1A2 4551/4885
US-20140031361-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 CYP11B2 1337/4885CYP11B1 1249/4885CYP1A2 1714/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP CYP11B2 1579/4885CYP11B1 1168/4885CYP1A2 540/4885
US-20150094298-A1 INHIBITORS OF PROTEIN KINASES SYK, BTK, JAK1 CYP11B2 1337/4885CYP11B1 1249/4885CYP1A2 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.